A phase II trial of pemetrexed in combination with gemcitabine as first line treatment in extensive-stage small cell lung carcinoma

Trial Profile

A phase II trial of pemetrexed in combination with gemcitabine as first line treatment in extensive-stage small cell lung carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Gemcitabine; Pemetrexed
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2007 Status change from recruiting to discontinued; due to a failure to accrue.
    • 30 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top